AMGN - Amgen Inc.
| Previous Close | 202.72 |
| Open | 202.74 |
| Bid | 198.05 x 800 |
| Ask | 201.65 x 900 |
| Day's Range | 201.47 - 205.12 |
| 52 Week Range | 163.31 - 210.19 |
| Volume | 2,157,782 |
| Avg. Volume | 2,520,120 |
| Market Cap | 130.619B |
| Beta (3Y Monthly) | 1.53 |
| PE Ratio (TTM) | 60.46 |
| EPS (TTM) | 3.34 |
| Earnings Date | Oct 30, 2018 |
| Forward Dividend & Yield | 5.28 (2.60%) |
| Ex-Dividend Date | 2018-08-16 |
| 1y Target Est | 205.15 |
- Zacks•14 hours ago
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
Amgen (AMGN) closed the most recent trading day at $201.80, moving -0.45% from the previous trading session.
- Market Realist•19 hours ago
Biogen: Revenue Growth Is Expected in Q3
As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.
- Investopedia•19 hours ago
Biotech Sector Could Enter Bear Market
Biotech price action at all capitalization levels has deteriorated in recent weeks, with the two major sector funds giving up the majority of their 2018 gains. The iShares Nasdaq Biotechnology Index Fund ( IBB) and the SPDR S&P Biotech ETF ( XBI) carve different price patterns due to their unique holdings and construction. The market-cap weighted Nasdaq fund is dependent upon its biggest components, with Amgen Inc. ( AMGN), Gilead Sciences, Inc. ( GILD), Biogen Inc. ( BGEN) and Celgene Corporation ( CELG) comprising more than 32% of portfolio weighting.
- Market Realist•20 hours ago
Analyzing Biogen before Its Third-Quarter Earnings
Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.
- Zacks•22 hours ago
AMGN or ILMN: Which Is the Better Value Stock Right Now?
AMGN vs. ILMN: Which Stock Is the Better Value Option?
- Kiplinger•23 hours ago
10 S&P 500 Stocks to Buy for the Long Term
The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance
- GlobeNewswire•yesterday
Investor Expectations to Drive Momentum within Amgen, Crown Castle International, Constellation Brands, Nice, NetEase, and The Hanover Insurance Group — Discovering Underlying Factors of Influence
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Market Realist•2 days ago
Novartis Missed Revenue Estimates in Q3 2018
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
- PR Newswire•2 days ago
Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies
THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores (nano-scale holes made by proteins contained within a synthetic membrane) in combination with electronics to perform direct, real-time sequencing of DNA and RNA. The investment in Oxford Nanopore aligns with Amgen's strategic focus on using human genetics to deliver new medicines to patients.
GuruFocus.com•3 days agoAmgen Launches Humira Biosimilar in Europe
Amgen (AMGN) soared 3.45% to $202.34 per share on Oct. 16 following the commercial launch of Amgevita in Europe. Amgevita is a biosimilar of AbbVie's (ABBV) Humira and the trade name of adalimumab. The product is used as a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, chronic psoriasis and other conditions.
- Reuters•3 days ago
Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.
Reuters•3 days agoExpress Scripts covers Amgen, Lilly migraine drugs, excludes Teva
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.
- Investing.com•3 days ago
Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
Investing.com - Stocks in focus in pre-market trade Wednesday:
- Zacks•3 days ago
Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?
Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.
- The Wall Street Journal•3 days ago
[$$] By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S.
Cheaper copies of the world’s biggest-selling drug will roll out across Europe this week after a key European patent for Humira expires Tuesday, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug. The reason: a formidable wall of patents built up by Humira-maker AbbVie Inc., that prevents the developers of “biosimilar” versions launching their products in the U.S. Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells in a process that resembles brewing.
- Investing.com•4 days ago
Amgen Rises 3%
Investing.com - Amgen (NASDAQ:AMGN) rose by 3.10% to trade at $201.66 by 14:31 (18:31 GMT) on Tuesday on the NASDAQ exchange.
Market Realist•4 days agoHow Nektar Therapeutics Is Positioned In October
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
- InvestorPlace•4 days ago
4 Strong Stocks to Buy That Double As Big Takeover Targets
One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.
- Benzinga•4 days ago
The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
- Reuters•4 days ago
Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU
Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.
- PR Newswire•4 days ago
Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe
THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC).
- Yahoo Finance•5 days ago
Trump administration: Drug makers should disclose prices in TV ads
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
- Zacks•5 days ago
Immune Design to Halt Cancer Vaccine Program, Shares Plunge
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
- Zacks•5 days ago
Top Ranked Income Stocks to Buy for October 15th
Top Ranked Income Stocks to Buy for October 15th
- Zacks•8 days ago
AbbVie Settles With Novartis to Delay Humira Biosimilar in US
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.
